Literature DB >> 28599438

Androgen deprivation therapy has no effect on Pim-1 expression in a mouse model of prostate cancer.

Jiang Wang1,2, Gang Li1, Bo Li1, Hualin Song1, Zhiqun Shang1, Ning Jiang1, Yuanjie Niu1.   

Abstract

The aim of the present study was to observe the dynamic changes of proto-oncogene, serine/threonine kinase, Pim-1 at the gene and protein level in a mouse model of prostate cancer following surgical castration. Using LNCaP cells to establish a subcutaneous xenograft model and orthotopic prostate cancer BALB/c nude mouse models, the xenograft models were divided into an androgen-dependent prostate cancer group (ADPC), an androgen deprivation therapy (ADT) group and an androgen independent prostate cancer (AIPC) group. Reverse transcription-polymerase chain reaction (RT-PCR), RT-quantitative PCR, ELISA and immunohistochemistry analyses were performed to compare the expression levels of Pim-1, prostate-specific antigen (PSA) and androgen receptor (AR) in tumor tissue of three subgroups. Agarose gel electrophoresis revealed that the RT-PCR results of the ADPC (0.59±0.01) and AIPC groups (1.14±0.015) were significantly different when compared with the ADT group (0.62±0.026; P<0.05). As for RT-qPCR, the ΔCq of Pim-1 in the ADPC (6.15±0.34) and AIPC (4.56±0.23) groups were significantly different compared with the ADT group (5.11±0.21; P<0.05). Using 2-ΔΔCq as a relative quantification method to analyze the data, the amplification products of Pim-1 increased by 2.05 and 3.01 times in the ADT and AIPC groups, respectively. ELISA demonstrated the following: The serum concentration of PSA was 0 ng/ml in the control group, 0.48±0.025 ng/ml in the ADPC group and 0.87±0.023 ng/ml in the AIPC group, which were significantly different compared with the ADT group (0.17±0.032 ng/ml; P<0.01). Upon immunohistochemical staining, the protein expression levels of Pim-1 and AR, respectively, were 0.017±0.0021 and 0.032±0.009 in the ADPC group, 0.024±0.0019 and 0.040±0.011 in the AIPC group, and 0.018±0.0013 and 0.019±0.006 in the ADT group. The protein levels of Pim-1 and AR in the ADPC and AIPC groups were significantly different compared with the ADT group (P<0.01). In addition, an orthotopic prostate cancer animal model of ADT was successfully established in the current study, and further investigation revealed that ADT did not affect the expression of Pim-1 at the gene or protein levels; thus, it is hypothesized that Pim-1 may be important in the proliferation and differentiation of prostate cancer during ADT.

Entities:  

Keywords:  LNCaP cell; Pim-1; androgen deprivation therapy; androgen independent prostate cancer; androgen receptor; androgen-dependent prostate cancer; animal model; orthotopic implanting

Year:  2017        PMID: 28599438      PMCID: PMC5453061          DOI: 10.3892/ol.2017.6010

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  28 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Effect size, confidence interval and statistical significance: a practical guide for biologists.

Authors:  Shinichi Nakagawa; Innes C Cuthill
Journal:  Biol Rev Camb Philos Soc       Date:  2007-11

3.  Overexpression of PIM-1 is a potential biomarker in prostate carcinoma.

Authors:  Yong Xu; Tong Zhang; Hua Tang; Shumin Zhang; Min Liu; Dalin Ren; Yuanjie Niu
Journal:  J Surg Oncol       Date:  2005-12-15       Impact factor: 3.454

Review 4.  Reconsideration of progression to CRPC during androgen deprivation therapy.

Authors:  Atsushi Mizokami; Mikio Namiki
Journal:  J Steroid Biochem Mol Biol       Date:  2014-04-06       Impact factor: 4.292

5.  Overexpression of Pim-1 during progression of prostatic adenocarcinoma.

Authors:  T L Cibull; T D Jones; L Li; J N Eble; L Ann Baldridge; S R Malott; Y Luo; L Cheng
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

6.  Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma.

Authors:  J Wang; J Kim; M Roh; O E Franco; S W Hayward; M L Wills; S A Abdulkadir
Journal:  Oncogene       Date:  2010-02-08       Impact factor: 9.867

7.  The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells.

Authors:  Marina Zemskova; Eva Sahakian; Svetlana Bashkirova; Michael Lilly
Journal:  J Biol Chem       Date:  2008-04-21       Impact factor: 5.157

8.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

Review 9.  PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.

Authors:  Sheldon L Holder; Sarki A Abdulkadir
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

10.  Real-time quantitative RT-PCR assessment of PIM-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer.

Authors:  Hui-chan He; Xue-cheng Bi; Zhi-wei Zheng; Qi-shan Dai; Zhao-Dong Han; Yu-Xiang Liang; Yong-Kang Ye; Guo-hua Zeng; Gang Zhu; Wei-de Zhong
Journal:  Med Oncol       Date:  2008-11-12       Impact factor: 3.064

View more
  4 in total

1.  Reduced pim-1 expression increases chemotherapeutic drug sensitivity in human androgen-independent prostate cancer cells by inducing apoptosis.

Authors:  Xing Zhang; Yuyan Sun; Peng Wang; Changfu Yang; Shengwei Li
Journal:  Exp Ther Med       Date:  2019-08-07       Impact factor: 2.447

Review 2.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

3.  Antiprostate Cancer Activity of Ineupatolide Isolated from Carpesium cernuum L.

Authors:  Yuan-She Huang; Jing-Xin Mao; Lai Zhang; Hong-Wei Guo; Chen Yan; Min Chen
Journal:  Biomed Res Int       Date:  2021-04-29       Impact factor: 3.411

Review 4.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.